Similarly, Palbociclib, a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), leads to inhibition of head and neck tumour cell proliferation by inducing cell cycle arrest. Here, CDK4 is linked to head and neck neoplasm.